Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma

Current treatments for glioblastoma multiforme (GBM)—an aggressive form of brain cancer—are minimally effective and yield a median survival of 14.6 months and a two-year survival rate of 30%. Given the severity of GBM and the limitations of its treatment, there is a need for the discovery of novel d...

Full description

Saved in:
Bibliographic Details
Published in:PLoS One
Main Authors: Jones, DeAnalisa C., Scanteianu, Adriana, DiStefano, Matthew, Bouhaddou, Mehdi, Birtwistle, Marc R.
Format: Artigo
Language:Inglês
Published: Public Library of Science 2018
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5771580/
https://ncbi.nlm.nih.gov/pubmed/29342193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0190664
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items